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ABSTRACT 
 
Osteoporosis in post-menopausal women is not merely due to deficient  estrogen 
hormone production. The development of osteoporosis is due to increased  bone 
resorption by osteoclasts. The osteoclast’s number and activity is controlled by activating 
factors such as IL-6 and RANK-L. The objective of this study was to determine that high 
IL-6 and RANK-L serum concentrations are risks for osteoporosis in estrogen deficient 
post-menopausal women. The serum concentration of ß-CrossLaps (CTx) was measured 
to determine bone resorption rate. This is an observational analytical study using case and 
control design conducted at Sanglah General Hospital of Denpasar. The sample size was 
calculated using the paired case-control study formula. There were 41 osteoporotic and 
41 non-osteoporotic (control) estrogen deficient post-menopausal women involved in the 
study.  
Data were analyzed by  using the t-paired and McNemar tests. Mean serum 
concentration of IL-6 among the osteoporotic women was significantly higher as 
compared to that of the controls (3.47±1.75 pg/ml vs 2.51±1.13 pg/ml, p = 0.001).  Mean 
serum concentration of  RANK-L among the osteoporotic women was also  significantly 
higher as compared to that of the controls (320.66±122.44ng/ml vs  249.94±82.41 ng/ml, 
p = 0.002). To qualify as risk factors for osteoporosis, the cut-off point for IL-6 was 2.17 
pg/ml (OR = 4, CI 95%: 1.23-14.24; p = 0.032); the cut-off point for RANK-L was 
275.165 ng/ml (OR = 8, CI 95%: 1.84-34.79; p = 0.001). Analysis of both high serum 
concentration of IL-6 and RANK-L was associated with an odd ratio of 9 (CI 95%: 4,27-
18,96, p=0,000). CTx concentration in the osteoporotic women was significantly higher 
than in the controls (0.60±0.22ng/ml vs 0.46±0.16ng/ml, p = 0.004).  
We found that the high IL-6 and RANK-L serum concentrations were risk factors 
in estrogen deficient post-menopausal women. CTx being a marker for osteoclastic bone 
resorption activity, increased in concentration higher in osteoporotic than in non- 
osteoporotic women. The high serum concentrations of IL-6 and RANK-L could be used 
as predictors for osteoporosis  in estrogen deficient post-menopausal women. 
 
Keywords:  Post-menopausal osteoporosis, estrogen, osteoclast activity, ß-Cross, (CTx), 
Interleukine-6, RANK-Ligand 
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INTRODUCTION 
Osteoporosis is a major health 
problem second only to cardiovascular 
disease (WHO, 1994). The prevalence of 
osteoporosis based on the study of Djoko 
Roeshadi (1997) by measuring bone 
mineral density is 26%.  Osteoporosis in 
post-menopausal women is thought to be 
due to estrogen deficiency. However 
many estrogen deficient post-meno 
pausal women are not afflicted with 
osteoporosis. Wardiana (2004) found 
that 78,9% post-menopausal women had 
low estradiol concentration (< 40 pg/ml) 
in whom only 25% were associated with 
increased bone resorption rate leading up  
to osteoporosis. 
Osteoporosis is due to the 
osteoclasts being more active than 
osteoblasts (Manolagas, 2000). IL-6 dan 
RANK-L are mediators which stimulate 
the differentiation process from 
osteoclast precursor cell to become 
active osteoclast  which resorps bone as 
shown by the increase of CTx serum 
concentration and then ends up in 
osteoporosis. (Baylink, 1999; Jilka, 
2001; Aubin & Bonnelye 2002; Jones et 
al, 2002; Manolagas et al, 2002).  
Until recently, it is not yet known 
whether IL-6, RANK-L and  CTx serum 
concentrations are higher in estrogen 
deficient post-menopausal women asso 
ciated with osteoporosis. 
 
Study Design 
This study is an observational 
analytical study using case and control 
design with estrogen deficient post-
menopausal women with osteoporosis as 
the case and without osteoporosis as the 
control group. 
 
RESULTS 
IL-6, RANK-Ligand, and CTx 
concentrations  
 
The difference in IL-6, RANK-Ligand 
and CTx concentrations between the 
case and control was analyzed using the 
paired–test with significant level α = 
0.05. Data analysis showed that IL-6, 
RANK-Ligand and CTx concentrations 
were higher in the case as compared to 
those in the control. They were 
statistically significant as the p value 
from mean difference from those three 
variables were less than the α value (p < 
0.05, Tabel  1). 
 
 
Table 1  Mean difference between IL-6, RANK-Ligand,  
and CTx concentrations between case and control 
 
Independent 
variable 
Mean and SD T 
statistic 
P value 
Case Control 
IL-6 (pg/ml) 3.47±1.75 2.51±1.13 3.558 .001 
RANK-Ligand 
(ng/ml) 
320.66±122.44 249.94±82.41 3.364 .002 
CTx (ng/ml) 0.60±0.22 0.46±0.16 3.098 .004 
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Osteoporosis Risk Factors 
Bivariate Analysis (McNemar) 
 
IL-6 and Osteoporosis 
 
Table 2  Case-control cross table according to IL-6 concentration 
 
 Case 
Control Total 
      > 2.17     < 2.17 
 > 2.17 18 12 30 
 < 2.17 3 8 11 
Total 21 20 41 
 
OR = 4 (CI 95%: 1.23-14.24) and p = 0.032 
 
Using 2.17 as cut-off point for IL-6 
concentration, we found the OR between 
estrogen deficient post-menopausal 
women with IL-6 concentration same as 
or above 2.17 and below 2.17 was 4 (CI 
95%: 1.23-14.24). Statistically the OR 
was significant with p < 0.05 (p = 0.032) 
using McNemar test (Table 2). 
 
 
RANK-L and Osteoporosis  
 
From association analysis between 
RANK-L concentration and osteoporosis 
in the estrogen deficient post-
menopausal women using cut off point 
275.165, we found the OR = 8 (CI 95%: 
1.84–34.79) and p < 0.05 (p = 0.001, 
Table 3).   
 
 
Table  3  Case-control cross table according to RANK-L concentration  
 
RANK-L concentration 
(Case)  
RANK-L concentration 
(Control) Total 
  > 275,165 < 275,165 
 > 275,165 12 16 28 
  < 275,165 2 11 13 
Total 14 27 41 
OR = 8 (CI 95%: 1.84–34.79) and p= 0.001 
 
4 
 
Both high IL-6 and RANK-L toward 
Osteoporosis 
 
From association analysis, both 
high IL-6 and RANK-L concentrations 
gave OR as high as 9 (CI 95%: 4.27-
18.96, p=0,000) for osteoporosis in 
estrogen deficient post-menopausal 
women (Table 4). 
 
     Table 4  Case and control cross table for both high IL-6 and RANK-L 
concentrations 
 
IL-6 and RANK-L 
concentrations in Case 
 
 
IL-6 and RANK-L 
concentrations in Control 
 
Total 
 
  
IL-6 and 
RANK-L 
increase 
Both not 
increase 
Case IL-6 and RANK-L 
increase 
4 18 22 
   
Both not increase 
 
2 17 19 
Total 6 35 41 
OR = 9 (CI 95%: 4.27–18.96) and p= 0,000 
 
DISCUSSION 
High IL-6 serum concentration as risk 
factor for osteoporosis 
From this study we found the 
mean concentrations and standard 
deviation for case and control were 
respectively 3.47±1.75pg/ml and 
2.51±1.13pg/ml. Assessed by using the 
t-paired test with significant level α = 
0.05, we found that those differences 
were statistically significant with p value 
of less than α = 0.05 (p = 0.001). For 
risk factor, analysis using McNemar test 
was conducted and using 2.17 as cut-off 
point for IL-6 concentration, we found 
the OR between IL-6 concentration 
equal to or above 2.17 and below 2.17 
was 4 (CI 95%: 1.23-14.24). Statistically 
the OR was significant with p < 0.05 (p 
= 0.03, Table 2). 
Interleukine-6 in spite of its roles 
in inflammatory and immunologic 
process, also plays a part in bone meta 
bolism through osteoclastogenesis 
induction and stimulate osteoclast 
activity (Keller, 1996). Interleukine-6 
increases the formation of osteoclast 
especially when there is decreased 
estrogen hormone concentration (Roitt et 
al, 1998; Pfeilschifter et.al, 2002). From 
these studies it was thought that IL-6 
was one among many cytokines which 
had important role in bone resorption 
through the increased osteoclast 
formation and activity.  
Maggio et al, (2006) conducted 
study in elderly males on the association 
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between testosterone hormone concen 
tration with IL-6 concentration. They 
found significant association: the older 
the person and the lower the testosterone 
level the higher the IL-6 concentration 
and lesser bone mass. It showed that 
systemic inflammatory sign especially 
CRP (C-reactive protein) and IL-6 could 
predict bone mass loss (Ding et al, 
2008). HIV infection was also related to 
bone mass loss in the spine and hip and 
an increase of bone turnover due to 
increased pro-inflammatory factor (such 
as IL-6)  (Dolan, et al, 2006). 
So from this study we inferred 
that in estrogen deficient post-
menopausal  women, high IL-6 was 
considered as risk factors for osteo 
porosis. We found that estrogen deficient 
post-menopausal women with IL-6 
concentration ≥ 2.17 pg/ml (cut off 
point) had OR as high as 4 (CI 95%: 
1.23–14.24, p = 0.03), meaning that their 
risk to develop osteoporosis was 4 times 
higher than the those with < 2.17 pg/ml.  
 
High RANK-L serum concentration as 
risk factor for osteoporosis 
We found that RANK-L mean 
concentration in the osteoporotic women 
was higher than in the controls: 
320.66±122.44 ng/ml vs 249±82.41 
ng/ml. Analysis using the t-paired test 
with level of significance α = 0.05, 
revealed that the mean difference was 
significant (p = 0,002, Table 1). To 
determine that RANK-L is a risk factor 
for osteoporosis in estrogen deficient 
post-menopausal women, the association 
between RANK-L concentration and 
osteoporosis data were analyzed using 
the McNemar test.and RANK-L 
concentration as high as 275.165ng/ml 
used as the cut off point. We found OR 
as high as 8 (CI 95%: 1.84-34.79) with p 
= 0.001 (p< 0.05) which was statistically 
significant  (Table 3). 
Osteoporosis develops due to 
increased osteoclastic bone resorption. 
Osteoclast is a member of monocyte or 
macrophage family and its different 
tiation and activation depend on 
essential cytokines such as: RANK-L 
and M-CSF  (Teitelbaum, 2007). Buxton 
et al. (2004) found increase of RANK-L 
and IL-6 concentrations and decrease of 
Osteoprotegerin (OPG) level on 51 post-
menopausal women who had  received 
PTH (parathyroid hormone) for 12 
months. RANK-L was more stable and 
consistent as osteoclast differentiation 
and activation factors and produces more 
risk for osteoporosis. Even Nakchbandi, 
et al. (2008) found that certain level of 
RANK-L serum concentration can be 
used as parameter to determine bone loss 
in primary hyperparathyroid patients.  
In our study we found that 
RANK-L serum concentration was 
higher in the estrogen deficient post-
menopausal women with osteoporosis as 
compared to than in the controls, thus 
RANK-L was a risk factor for 
osteoporosis. Subjects with RANK-L 
concentration ≥ 275.165 ng/ml (cut off 
point) had OR as high as 8 (CI 95%: 
1.84-34.79, p=0.001), meaning that the 
subjects had risk for osteoporosis 8 times 
higher than those with less than 275.165 
ng/ml.  
 
IL-6 and RANK-L combined as risk 
factors for osteoporosis 
To determine that both IL-6 and RANK-
L high concentrations are risk factors for 
osteoporosis in estrogen deficient post-
menopausal women, the association 
between both IL-6 and RANK-L high 
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concentration and osteoporosis was 
analyzed using McNemar test using the 
IL-6 and RANK-L cut off points. We 
found the OR as high as 9 (CI 95%: 
4.27-18.96, p=0.000) which was 
statistically significant (Table 4). 
The results imply that estrogen 
deficient post-menopausal women with 
IL-6 and RANK-L concentrations above 
the cut off point had increased risk for 
osteoporosis up to 9 times as compared 
to those with level below the cut off 
point. This is due to the synergic nature 
of cytokines (Karnen, 2000; Siti, 2001). 
So in this study we found that IL-6 and 
RANK-L had synergic effect to 
influence the activity of the osteoclasts. 
 
CTx concentration is higher in 
estrogen deficient post-menopausal 
women with osteoporosis compared to 
those without osteoporosis 
We measured the levels of CTx as 
indicator of bone resorption rate and 
compared the levels in the estrogen 
deficient post-menopausal women with 
osteoporosis and in the controls; and we 
found that CTx concentration in the 
osteoporotic women was higher than in 
the control, 0.60±0.22 ng/ml vs 
0.46±0.16 ng/ml. Analysis using the t-
paired test with level of significance α = 
0.05, reveled that the mean difference 
for CTx between the case and the control 
was statistically significant (p = 0.004, 
Table 1). This implies that bone 
resorption rate due to osteoclast activity 
was higher in estrogen deficient post-
menopausal women with osteoporosis as 
compared to those without osteoporosis.  
In fact Riggs & Khosla (1995) 
has already suggested that in measuring 
women with high risk for osteoporosis, 
the most important thing is to determine 
the increase of bone resorption rate. 
CTx, a byproduct of bone collagen type 
I, is a good indicator to determine bone 
resorption rate. (Kaniawati & 
Moeliandari, 2003; Roche Diagnostics, 
2003b). CTx as bone resorption marker 
was shown by decreasing osteoclast 
activity. Giving anti-resorption drug 
such as Zoledronic acid to osteoporotic 
post-menopausal women for 1 month, 
they found a decrease in CTx serum 
concentration as compared to those with 
placebo (Reid et al, 2002). It implies that 
CTx as byproduct of bone resorption 
was not produced in that study.  
From all studies cited above, we 
may infer that CTx serum concentration 
is a good indicator for bone resorption 
rate. Our study revealed that CTx in 
estrogen deficient post-menopausal 
women with osteoporosis was 
significantly higher in the case than in 
the control. This implies that osteoclast 
induced resorption of was more active in 
the osteoporotic women as compared to 
the control.  
 
Novelty of the Study 
The developmental mechanism of 
osteoporosis in estrogen deficient post-
menopausal women was shown to be 
closely associated with increase of IL-6 
and RANK-L serum concentrations. 
This implies that high serum 
concentrations of IL-6 and RANK-L will 
stimulate osteoclast differentiation and 
activation. The osteoclast’s number and 
activity lead to increased bone resorption 
thus increasing the risk for osteoporosis. 
CTx as bone collagen type I derivation 
which serves as bone resorption 
indicator can be detected in the serum. 
Therefore we infer that high 
serum concentrations of IL-6 and 
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RANK-L are risk factors for 
osteoporosis in estrogen deficient post-
menopausal women 
 
CONCLUSIONS 
 
IL-6 and RANK-L concentra 
tions were significantly higher in 
osteoporotic estrogen-deficient post-
menopausal women as compared to 
those without. osteoporosis.  
Being a marker for osteoclastic 
bone resorption activity, CTx concen 
tration was shown to be higher in 
osteoporosis. 
The developmental mechanism 
of osteoporosis in estrogen deficient 
post-menopausal women appears to 
be closely related to increased IL-6 
and RANK-L serum concentrations.  
IL-6 and RANK-L could be used 
as predictors to increase our awa 
reness for the possible occurrence of 
osteoporosis in post-menopausal 
women.  
. 
SUGGESTIONS 
It is suggested that high IL-6 and 
RANK-L serum concentrations are risk 
factors for osteoporosis which might 
have immediate clinical implications; 
this implies that changing the factors 
might have some impact on the develop 
pment of osteoporosis.. 
To qualify increased IL-6 and 
RANK-L as risks for osteoporosis in 
estrogen deficient post-menopausal 
women, a study with a larger sample is 
required. 
Morrow and de Lennox (2007) 
have set out three criteria a biomarker 
should fulfill to be useful clinically: (1) 
accurate, repeated measurements must 
be available to the clinician at a 
reasonable cost and with short 
turnaround times, (2) biomarker must 
provide information that is not already 
available from a careful clinical 
assessment, and (3) knowing the 
measured level should aid in medical 
decision making.  
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